Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Other Non Operating Income: 2014-2024

Historic Other Non Operating Income for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to $41.0 million.

  • Viking Therapeutics' Other Non Operating Income fell 33.08% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.4 million, marking a year-over-year increase of 7.56%. This contributed to the annual value of $41.0 million for FY2024, which is 174.30% up from last year.
  • According to the latest figures from FY2024, Viking Therapeutics' Other Non Operating Income is $41.0 million, which was up 174.30% from $14.9 million recorded in FY2023.
  • In the past 5 years, Viking Therapeutics' Other Non Operating Income registered a high of $41.0 million during FY2024, and its lowest value of $692,000 during FY2021.
  • For the 3-year period, Viking Therapeutics' Other Non Operating Income averaged around $19.1 million, with its median value being $14.9 million (2023).
  • In the last 5 years, Viking Therapeutics' Other Non Operating Income crashed by 78.15% in 2021 and then surged by 903.49% in 2023.
  • Viking Therapeutics' Other Non Operating Income (Yearly) stood at $3.2 million in 2020, then crashed by 78.15% to $692,000 in 2021, then skyrocketed by 115.03% to $1.5 million in 2022, then surged by 903.49% to $14.9 million in 2023, then surged by 174.30% to $41.0 million in 2024.